STADA

Products

Products

STADA directly supplies MOVAPO® (apomorphine hydrochloride) and Ropivacane ReadyfusOR in Australia.

STADA directly supplies MOVAPO® (apomorphine hydrochloride) and Ropivacaine ReadyfusOR in Australia.

At STADA Australia, we launched our specialty products, focused on the treatment of Parkinson’s disease, in Australia and New Zealand in 2016 and in August 2017, we expanded our portfolio to include Pain Management.

We work closely with Britannia Pharmaceuticals and BioQ Pharma to bring innovative therapies and the latest advancements to Australia and New Zealand.

Our products

STADA directly supplies MOVAPO® (apomorphine hydrochloride) and Ropivacaine ReadyfusOR in Australia. To learn more, please browse the following resources:

Research and development

We invest in research and development to deliver innovative therapies that address the unmet needs of patients and their carers.

Contact us

For all enquiries, please phone 1800 791 660 or email medinfo(at)stada.com.au

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Learn more

Sustainability

Sustainability

For STADA "All the best" means taking responsibility.

Learn more

entdecken